Loading
Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.
Nicholas James is Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden. His specialisms are prostate cancer, bladder cancer, multi-arm platform trials and radiotherapy. He is chief investigator of STAMPEDE, the multi-arm multi-stage platform trial that established docetaxel and abiraterone in hormone-sensitive metastatic prostate cancer, with the New England Journal of Medicine paper reporting abiraterone for prostate cancer not previously treated with hormone therapy. He has also led trials of chemoradiotherapy in bladder and urothelial cancer. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE) | NEJM | 2017 |
Men diagnosed with prostate cancer that has already spread, or that is locally advanced and high risk, should start abiraterone (or another androgen-receptor pathway inhibitor) at the same time as testosterone suppression rather than waiting for resistance. This roughly halves the risk of death over several years. The same platform later showed that docetaxel chemotherapy and, in high-volume metastatic disease, triple therapy also help, and that abiraterone benefits men with high-risk disease treated with radiotherapy.
The answer to a question three individual trials could not answer on their own, and the reason docetaxel with androgen deprivation became standard for metastatic hormone-sensitive disease. It also stopped a widely used bone drug being credited with a survival effect it does not have.
The end of therapeutic nihilism in castration-resistant prostate cancer. It is also the trial that set the field's expectation of what a positive result looks like in this disease: a hazard ratio near 0.75 and a median gain measured in months, not years.
Shares STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer, Master protocol (platform, basket and umbrella trials), STAMPEDE, University College London Hospitals / UCL Cancer Institute.
Shares Nicholas van As, The Institute of Cancer Research, The Royal Marsden, Prostate cancer.
Shares Nicholas van As, STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer, The Institute of Cancer Research, The Royal Marsden.
Shares STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis, STAMPEDE, Prostate cancer.
Shares STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis, TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, Prostate cancer.
Shares STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer, STAMPEDE, Prostate cancer.
Shares TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, Docetaxel, Prostate cancer.
Shares STAMPEDE, University College London Hospitals / UCL Cancer Institute, Prostate cancer.